Dr. Dasgupta is a highly regarded professor in New York University School of Medicine with more than a decade of experience in cancer research and drug discovery. In March 2016, his proprietary compounds were licensed to iβeCa Therapeutics, a spin-off which is venture-funded by Allied-Bristol Life Sciences. In 2014, Dr. Dasgupta joined the Genome Institute of Singapore, A*STAR as a Senior Investigator, where he established the Centre for High-throughput Phenomics and the Perkin Elmer-GIS Joint Centre for Precision Oncology to develop new evidence-based paradigms for the treatment of cancers. He will be contributing to our scientific development of the Onco-PDO™ personalised drug screening technology. Dr. Dasgupta is the recipient of several national and international awards such as the Harold Weintraub award, Breast Cancer Research Foundation Concept Award (USA), NYSTEM Idea Award, ACS Research Scholar Award (USA), March of Dimes Research Grant, the NYC BioAccelerate Prize, and the Wellcome Trust International Senior Research Fellowship, amongst others.

  cancer research and drug discovery,  Precision Oncology, personalised drug screening